Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market and Novo Nordisk has faced lower prescriptions of Wegovy than expected.
Quartz on MSN1d
A new stronger Ozempic is coming. Here's what to knowNovo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...
Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...
Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...
Bloomberg L.P. on MSN9d
Novo Nordisk Shares Seen Outpacing Lilly’s After Summer StumbleNovo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity ...
It isn’t that Wall Street doubts the massive opportunity to treat hundreds of millions of people with obesity worldwide; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback